1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S272000, C514S239200, C514S232200, C514S234200, C514S235500, C514S319000, C514S217050, C514S357000, C544S123000, C544S321000, C544S131000, C544S079000, C544S070000, C544S121000, C544S165000, C544S129000, C544S230000, C544S273000, C546S206000, C546S194000, C546S337000, C540S598000

Reexamination Certificate

active

07829560

ABSTRACT:
1,4 disubstituted napthylenes, of formula (I), are disclosed. These compounds may be useful in treating cell-proliferative diseases.

REFERENCES:
patent: 3455924 (1969-07-01), Ladnicer
patent: 4794114 (1988-12-01), Bender et al.
patent: 4892578 (1990-01-01), Chang et al.
patent: 5317019 (1994-05-01), Bender et al.
patent: 5777097 (1998-07-01), Lee et al.
patent: 5783664 (1998-07-01), Lee et al.
patent: 5869043 (1999-02-01), McDonnell et al.
patent: 5871934 (1999-02-01), Lee et al.
patent: 5955366 (1999-09-01), Lee et al.
patent: 5994412 (1999-11-01), Lee et al.
patent: 6033873 (2000-03-01), McDonnell et al.
patent: 6090626 (2000-07-01), Monia et al.
patent: 6162613 (2000-12-01), Su et al.
patent: 6187799 (2001-02-01), Wood et al.
patent: 6302838 (2001-10-01), O'Reilly et al.
patent: 6344476 (2002-02-01), Ranges et al.
patent: 6376214 (2002-04-01), Kumar
patent: 6387641 (2002-05-01), Bellon et al.
patent: 6410518 (2002-06-01), Monia
patent: 6437147 (2002-08-01), Andersen et al.
patent: 6683100 (2004-01-01), van Hoogevest
patent: 6689883 (2004-02-01), Boyer et al.
patent: 6806258 (2004-10-01), Monia
patent: 2001/0006975 (2001-07-01), Wood et al.
patent: 2002/0042517 (2002-04-01), Uday et al.
patent: 2002/0058659 (2002-05-01), Andersen et al.
patent: 2002/0137774 (2002-09-01), Riedl et al.
patent: 2002/0165394 (2002-11-01), Dumas et al.
patent: 2003/0078432 (2003-04-01), Letavic et al.
patent: 2003/0125359 (2003-07-01), Lyons et al.
patent: 2003/0144278 (2003-07-01), Riedl et al.
patent: 2003/0181442 (2003-09-01), Riedl et al.
patent: 2003/0207872 (2003-11-01), Riedl et al.
patent: 2003/0207914 (2003-11-01), Dumas et al.
patent: 2003/0216396 (2003-11-01), Dumas et al.
patent: 2003/0216446 (2003-11-01), Dumas et al.
patent: 2004/0023961 (2004-02-01), Dumas et al.
patent: 2004/0087626 (2004-05-01), Renhowe et al.
patent: 2004/0122237 (2004-06-01), Amiri et al.
patent: 0 951 467 (2003-04-01), None
patent: 1 114 051 (2003-04-01), None
patent: 1 449 834 (2004-08-01), None
patent: 61214793 (1987-02-01), None
patent: WO 91/00092 (1991-01-01), None
patent: WO 95/03297 (1995-02-01), None
patent: WO 97/32604 (1997-09-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 98/52559 (1998-11-01), None
patent: WO 99/20624 (1999-04-01), None
patent: WO 99/32106 (1999-07-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32455 (1999-07-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/42012 (2000-07-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 02/04447 (2002-01-01), None
patent: WO 02/062763 (2002-08-01), None
patent: WO 02/083628 (2002-10-01), None
patent: WO 02/085857 (2002-10-01), None
patent: WO 03/000682 (2003-01-01), None
patent: WO 03/033502 (2003-04-01), None
patent: WO 03/047523 (2003-06-01), None
patent: WO 03/047579 (2003-06-01), None
patent: WO 03/068223 (2003-08-01), None
patent: WO 03/068229 (2003-08-01), None
patent: WO 03/068746 (2003-08-01), None
patent: WO 03/087087 (2003-10-01), None
patent: WO 03/102139 (2003-12-01), None
patent: WO 2004/014870 (2004-02-01), None
patent: WO 2004/019941 (2004-03-01), None
patent: WO 2004/037789 (2004-05-01), None
patent: WO 2004/072025 (2004-08-01), None
patent: WO 2004/080464 (2004-09-01), None
patent: WO 2004/085399 (2004-10-01), None
patent: WO 2004/087905 (2004-10-01), None
patent: WO 2004/089929 (2004-10-01), None
patent: WO 2005/023761 (2005-03-01), None
Schreiber, et al., Clin. Gastroenterol. Hepatol., Mar. 2006, 4(3): 325-334 (PubMed abstract).
Sun, et al., Exp. Neurol. Oct. 2003; 183(2): 394-405 (abstract).
Newton, et al., Drug Discovery Today: Disease Mechanisms, 2006, pp. 53-61.
See, et al., Drug Discovery Today: Disease Mechanisms, 2004, pp. 149-154.
Feldmann, Nature Immunology, vol. 2, No. 9, Sep. 2001, pp. 771-773.
Hashimoto, et al., J. of Pharmacol. & Exper. Therap., vol. 293, No. 2, pp. 370-375, 2000.
Johnson, et al., Science, vol. 298, Dec. 6, 2002, 1911-1912.
Yang, et al., J. Leukocyte Biol., 2005;78:1-8.
Dodeller, Arth. Res. & Therapy 2006, 8:205.
Adams et al., “Pyrimidinylimidazole Inhibitors of CSBP/p38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes,,”Bioorg. Med. Chem. Lett., 8:3111-3116 (1998).
Adams et al., “Pyrimidinylimidazole Inhibitors of p38: Cyclic N-1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity,”Bioorg. Med. Chem. Lett., 11:2867-2870 (2001).
Badger et al., “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function,”J. Pharmacol. Exp. Ther., 279:1453-1461 (1996).
Bingham, “The Pathogenesis of Rheumatoid Arthritis: Pivotal Cytokines Involved in Degradation and Inflammation,”J. Rheumatol. Suppl., 65:3-9 (2002).
Boehm et al., “New Inhibitors of p38 Kinase,”Expert Opinion on Therapeutic Patents, 10(1):25-37 (2000).
Bondeson et al., “Tumour Necrosis Factor as a Therapeutic Target in Rheumatoid Arthritis and Other Chronic Inflammatory Diseases: The Clinical Experience with Infliximab (REMICADE),”Int. J. Clin. Pract., 55:211-216 (2001).
Bradley and Robinson, Kationoid Reactivity of Aromatic Compounds. Part I, (Database Beilstein, Beilstein Institute zur Foerderung der Wissenschaften), Accession No. 316203,J. Chem. Soc. 1254-1263 (1932).
Brinkman et al., “Engagement of Tumor Necrosis Factor (TNF) Receptor 1 Leads to ATF-2- and p38 Mitogen-Activated Protein Kinase-Dependent TNF-alpha Gene Expressidn,”J. Biol. Chem., 274:30882-30886 (1999).
Dong et al., “MAP Kinases in the Immune Response,”Annu. Rev. Immunol., 20:55-72 (2002).
English et al., “Pharmacological Inhibitors of MAPK Pathways,”Trends in Pharmacological Sciences, 23:40-45 (2002).
Enslen et al., “Selective Activation of p38 Mitogen-Activated Protein (MAP) Kinase Isoforms by the MAP Kinase Kinases MKK3 and MKK6,”J. Biol. Chem., 273:1741-1748 (1998).
Feldmann et al., “Role of Cytokines in Rheumatoid Arthritis,”Annu. Rev. Immunol., 14:397-440 (1996).
Fresneda et al., “Synthetic Studies Towards the 2-Aminopyrimidine Alkaloids Variolins and Meridianins from Marine Origin,”Tetrahedron Letters, 41:4777-4780 (2000).
Fuchs et al., “Stability of the ATF2 Transcription Factor is Regulated by Phosphorylation and Dephosphorylation,”J. Biol. Chem., 275:12560-12564 (2000).
Griswold et al., “Differentiation in vivo of Classical Non-Steroidal Antiinflammatory Drugs from Cytokine Suppressive Antiinflammatory Drugs and Other Pharmacological Classes Using Mouse Tumour Necrosis Factor Alpha Production,”Drugs Exp. Clin. Res., 19:243-248 (1993).
International Search Report for International Application No. PCT/US2004/015368.
International Search Report for International Application No. PCT/US2004/024441.
International Search Report for International Application No. PCT/US2004/037390.
Joe et al., “Animal Models of Rheumatoid Arthritis and Related Inflammation,”Curr. Rheumatol. Rep., 1:139-148(1999).
Keesler et al., “Purification and Activation of Recombinant p38 Isoforms Alpha, Beta, Gamma, and Delta,”Protein Expr. Purif., 14:221-228 (1998).
Keffer et al., “Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis,”EMBO J., 10:4025-4031 (1991).
Laufer et al., “An in vitro Screening Assay for the Detection of Inhibitors of Proinflammatory Cytokine Synthesis: a Useful Tool for the Development of New Antiarthritic and Disease Modifying Drugs,”Osteoarthritis Cartilage, 10:961-967 (2002).
Laufer and Wagner, “From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release,”J. Med. Chem., 45:2733-2740 (2002).
Lee et al., “A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis,”Nature, 372:739-746 (1994).
Lee et al., “Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors,”Ann.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4214127

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.